Skip to Content
Morningstar

Moderna Inc MRNA Stock Quote

Morningstar Rating
| Rating as of

Morningstar‘s Stock Analysis MRNA

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Investor
Is it the right time to buy or sell?
Find out with Morningstar Investor

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

Moderna's Vaccine Portfolio Is Advancing, Supporting Our $232 Fair Value Estimate

Karen Andersen, CFA Sector Strategist

Business Strategy and Outlook

| Karen Andersen, CFA |

Moderna's mRNA technology has gained rapid validation as sales of its COVID-19 vaccine soared in 2021, but we think the firm has yet to secure a narrow economic moat around its business, largely due to uncertainties tied to an evolving virus and the changing competitive landscape for innovative vaccines.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics MRNA

More

Company Profile MRNA

Business Description

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 44 mRNA development programs as of early 2022, with 25 of these in clinical trials. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Contact
200 Technology Square
Cambridge, MA, 02139
T +1 617 714-6500
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Jun 30, 2022
Fiscal Year End Dec 31, 2022
Employees 2,700

Related Articles MRNA

Our Picks

33 Undervalued Stocks for 2022

Here’s the new list of Morningstar’s top analyst picks for the fourth quarter.
Susan Dziubinski
Fund Spy

How Has Private Equity Investing Fared for Mutual Funds?

Fund companies have embraced ownership of 'unicorn companies,' with mixed results.
Jack Shannon
Market Update

How a Top T. Rowe Price Manager Is Positioned for a Continued Bear Market

T. Rowe Price All-Cap Opportunities' Justin White holds stocks like Visa and Chubb, names he sees as both inflation- and recession-resistant.
Tom Lauricella
Market Update

8 Newly Undervalued 5-Star Stocks

Burlington Stores and Goldman Sachs stocks are among those looking more attractive as the bear market drives names further into undervalued territory.
Jakir Hossain
Commentary

Moderna Stock vs. Pfizer Stock: Which Is the Better Buy Now?

Both companies have been leaders in the fight against the coronavirus, but only one of their stocks is undervalued today.
Susan Dziubinski
Quarter-End Insights

Biopharma Stocks the Most Undervalued in Healthcare

The defensive nature and the relative safety of healthcare stocks are supporting the sector's outperformance.
Damien Conover
Stock Analyst Update

Moderna Shares Remain Undervalued Following Superior Data for Bivalent Omicron-Adapted Vaccine

While we’re encouraged by the firm’s progress and validation of its technology, we have yet to award the firm an economic moat.
Karen Andersen
Market Update

When Momentum Fails

The momentum factor has been a pretty unstoppable force, but nothing lasts forever.
Amy C. Arnott
Market Update

Cheap Stocks With Q1's Largest Fair Value Upgrades

Undervalued stocks in the financial, automobile, and semiconductor industries recently had major valuation increases.
Jakir Hossain
Stock Analyst Update

Boosting Our Moderna COVID-19 Vaccine Sales Projections

We are raising our fair value estimate for Moderna to $232.
Karen Andersen
Market Update

Markets Review/Preview: Yields March Higher, Oil Slides

Chinese ADRs bounce back, Nvidia and Moderna rise, and energy stocks slump.
Jakir Hossain
Stock Analyst Update

Raising Our Moderna FVE to $202; Shares Undervalued

We think Moderna is on its way to building a narrow moat, with a potential fourth vaccine dose and annual COVID-19 booster shots.
Karen Andersen
Market Update

Markets Review/Preview: Earnings and Russia Dominate

Sabre, DoorDash rally, while Roblox, Roku take a big hit.
Jakir Hossain
Stock Strategist Industry Reports

Will Vaccine Manufacturers' Windfalls Continue Beyond 2022?

We think the COVID-19 treatment market will have more longevity.
Karen Andersen
Investing Specialists

How Well Did the Retirement Saver Portfolios Perform in 2021?

All portfolios posted strong gains in absolute terms, but the ETF portfolios crushed their mutual fund counterparts.
Christine Benz
Investing Specialists

Weekly Wrap: Undervalued Stocks for 2022, Outlook for the Market and Economy, and Your 2022 Financial Calendars

And also Tesla.
Morningstar.com
Stock Analyst Update

Fair Value Increases for Pfizer, BioNTech, and Moderna

Increased contracts for COVID-related products are just part of the reason for the upgrades.
Damien Conover
Fund Spy

The Year in U.S. Stock Funds

Value is back.
Eric Schultz
Market Update

The Best Stocks of 2021 in Morningstar’s Coverage List

Moderna and BioNTech were among a top performers list dominated by tech, energy, and consumer names.
Jakir Hossain
Market Update

Forget Value vs. Growth--Size Drove Returns in 2021

Six charts showing how market cap drove returns.
Lauren Solberg

Related News - MRNA

More